About Neocytogen
Founded in 2024, Neocytogen Therapeutics is a biotechnology company focusing on universal cell and gene therapy, committed to developing innovative therapies for malignant tumors and chronic diseases. The company's core technologies include universal CAR-X platform, iPSC platform, next generation oncolytic virus platform, and exosome technology platform. The founding team of Neocytogen is composed of senior scientists from the National University of Singapore and Nanyang Technological University. The company is headquartered in Singapore, with R&D centers in Singapore and Shanghai, China. We are also building an integrated center of R&D and production in Singapore to support future technology translation and clinical applications, enabling us to become a global leader in universal cell therapy.
Latest News
Learn More →Join Us
Learn More →
Create the Future with Us
At Neocytogen Therapeutics, we are pioneering a new era in universal cell and gene therapy. If you are passionate about biopharmaceuticals and eager to showcase your talents in cutting-edge science, we invite you to join our team.
We offer a challenging work environment, competitive compensation, and the opportunity to work with industry-leading experts. Join us to become a global leader in universal cell therapy.